DSIP (Delta Sleep-Inducing Peptide)

Studied Benefits

Promotion of slow-wave (delta) sleep
Reduced sleep-onset latency in disturbed sleep
Normalization of disrupted sleep architecture
Stress-response modulation (HPA axis)
Studied adjunctively for chronic pain and withdrawal-related sleep disruption

Protocol At-a-Glance

Common Starting Dose: 0.1 mg (100 mcg) SubQ
Studied Range: 0.1–0.3 mg per dose
Frequency: Typically nightly, 30–60 min before bed
Timing: Pre-sleep
Fasting: Not required
Reconstitution: 2 mL BAC water per 5 mg vial
Storage: Refrigerate 2–8°C after reconstitution
Typical Cycle: 2–4 weeks on, then assess; often run in bursts rather than continuously
Route: Subcutaneous injection (intranasal and IV also studied)

⚠️ Start Low, Go Slow: DSIP has a very short half-life (~7 minutes) and individual response varies widely. Start at the low end of the studied range. Effects on sleep architecture are often subtle, don't stack dose on top of dose expecting a stronger sedative effect. DSIP is not a sedative; it modulates sleep rather than forcing it.

Overview

DSIP is a nonapeptide (9 amino acids) first isolated in 1977 from the cerebral venous blood of rabbits during induced sleep by Swiss researcher Guido Schoenenberger and colleagues. Its name comes directly from the context of its discovery, the peptide appeared to correlate with delta-wave (slow-wave) sleep activity.

Unlike benzodiazepines or other sedatives, DSIP does not cause unconsciousness or force sleep. Published research frames it as a sleep-modulating peptide that appears to normalize disrupted sleep architecture rather than sedate. It has also been studied for its broader neuropeptide effects on the stress axis, pain perception, and addiction-related sleep disturbance.

Despite decades of research, DSIP has never been commercialized as a pharmaceutical and is not FDA-approved. It remains in research-chemical territory, available only through compounding pharmacies or the peptide research market.

Plain-English Summary

Delta Sleep-Inducing Peptide. A nonapeptide first isolated in 1977, researched for improving sleep architecture, particularly deep/delta-wave sleep. Not FDA-approved. Has a very short half-life (about 7 minutes), so timing is important in research protocols.

Why people are looking into this peptide

What people typically want from it

People researching DSIP are usually struggling with deep sleep, stress-driven insomnia, or poor sleep quality despite good sleep habits. They typically want to:

Improve deep (slow-wave) sleep quality
Fall asleep faster and stay asleep longer
Reduce stress-driven insomnia
Wake up feeling actually rested
Use a non-sedative, non-addictive sleep support option

FDA / Regulatory Status

Not FDA-Approved As of April 2026.

DSIP is not approved by the FDA for any human indication. No IND (Investigational New Drug) application appears to be active in the US. It is not currently on the FDA 503A or 503B compounding lists as a bulk substance. Users in research contexts should be aware that its regulatory status is ambiguous.

Mechanism of Action

The precise mechanism of DSIP remains incompletely characterized despite decades of study. Proposed mechanisms based on published research include:

Modulation of sleep architecture: Increased delta-wave (stage 3-4 NREM) activity and improved sleep continuity in polysomnography studies.
HPA axis regulation: DSIP appears to dampen corticotropin-releasing hormone (CRH) and ACTH activity, reducing stress-related arousal.
Neurotransmitter interaction: Indirect effects on GABA, serotonin, and possibly endogenous opioid systems have been reported.
Circadian influence: Some data suggests DSIP interacts with melatonin regulation and pineal function.

DSIP crosses the blood-brain barrier, which is one reason peripheral administration (injection) can produce central nervous system effects.

Published Research Applications

Chronic insomnia: Improved sleep efficiency and slow-wave sleep percentage in small clinical trials.
Opioid withdrawal: Studied as an adjunct to reduce withdrawal-related insomnia and dysphoria.
Alcohol withdrawal: Similar adjunctive use reported in European literature.
Chronic pain syndromes: Studied for sleep improvement in pain patients where pain disrupts sleep architecture.
Stress and burnout: Preliminary research on HPA axis modulation.

Potential Side Effects

DSIP has a generally benign reported safety profile in published studies, though long-term data is limited.

Side Effect	Frequency	Severity	Notes
Injection site reaction	Common	Mild	Minor redness/irritation
Headache	Occasional	Mild	Usually transient
Dizziness	Occasional	Mild	Most often with higher doses
Paradoxical arousal	Uncommon	Moderate	Some users report feeling more awake rather than sleepy, may reflect dose timing or individual variability
GI discomfort	Rare	Mild	Reported inconsistently

Stacking Considerations

Common pairings discussed in research/peptide communities:

DSIP + CJC-1295 / Ipamorelin: Different mechanisms for sleep improvement. CJC/Ipa acts via the GH pulse (more deep-sleep reactivity), DSIP acts on sleep architecture directly. Some users find the combination synergistic for restorative sleep.
DSIP + Epitalon: Often discussed in longevity-focused protocols where circadian normalization is the goal.
DSIP + Selank: For users whose sleep disruption is primarily anxiety-driven.

No controlled trials have evaluated these combinations specifically, pairings are based on mechanism logic, not evidence.

Clinical Trial Status

No active registered US-based clinical trials for DSIP as of April 2026. Historical trial data comes primarily from European (Swiss, German, Russian) research dating from the 1980s and 1990s. Modern replication in Western peer-reviewed literature is limited. Search ClinicalTrials.gov for the most current information.

Commonly Studied Dosing Protocols

In published research, Delta Sleep-Inducing Peptide (DSIP) has been examined using diverse dosing regimens. Most human research originates from European studies conducted in the 1980s and 1990s, and modern replication in Western peer-reviewed literature is limited. The following represents commonly discussed dosing ranges based on published research:

Subcutaneous and Intramuscular Administration

Reported dosing ranges: 100 mcg to 4 mg per injection, typically administered subcutaneously (SubQ) or intramuscularly (IM). Frequency: Most published protocols involved single nightly injections, usually administered before bedtime. Some studies used multiple daily doses. Cycle length: Published studies typically involved treatment periods of 2–12 weeks of nightly dosing. Route: Subcutaneous or intramuscular injection. Evidence status: The published data on DSIP dosing comes primarily from European research and is dispersed across older literature sources. Dosing protocols varied considerably between studies, and no modern dose-response or dose-optimization trials have been conducted in Western peer-reviewed journals. The most frequently referenced dose range in older studies appears to be 100–500 mcg nightly (e.g., historical European research; precise PubMed documentation may be limited for non-English-language original reports).

Plasma Kinetics and Biological Effect Duration

DSIP is rapidly cleared from plasma (half-life approximately 7 minutes), yet published research suggests its biological effects persist longer than its circulating levels would predict. This discrepancy suggests possible tissue binding, receptor downregulation kinetics, or longer-lasting downstream signaling. This may explain why single nightly dosing was employed in studies despite the short circulatory half-life. However, the mechanistic basis for the prolonged effect remains unclear, and no modern pharmacokinetic studies have been conducted to clarify optimal dosing intervals.

Evidence Gaps

Modern human studies of DSIP dosing are lacking. The historical European research literature provides limited standardization regarding optimal doses, dosing frequency, or treatment duration. Replication of these findings in contemporary Western research settings has not occurred, partly due to DSIP's limited commercial availability and regulatory status outside of Russia and some European countries.

Evidence Status: Published human studies of DSIP dosing are historically limited and geographically concentrated. No modern dose-response or dose-optimization trials have been conducted in major English-language peer-reviewed journals. All reported dosing ranges represent historical research protocols and community convention rather than contemporary evidence-based guidelines.

Frequently Asked Questions

Is DSIP a sedative?

No. Published research describes DSIP as a sleep-modulating peptide rather than a sedative. It does not produce drowsiness in the way benzodiazepines or Z-drugs do. It appears to influence sleep architecture in people whose sleep is disrupted, with less effect in people with normal sleep.

Why is DSIP's half-life so short?

DSIP is rapidly cleared from plasma (half-life ~7 minutes). However, published studies suggest its biological effects last longer than plasma levels would predict, possibly because of tissue binding or downstream signaling cascades. This is why single nightly dosing appears to work despite the short circulatory half-life.

DSIP vs. melatonin, what's the difference?

Melatonin signals circadian phase (primarily affecting sleep onset timing). DSIP appears to affect sleep depth and architecture (slow-wave sleep in particular). They target different aspects of sleep and are not interchangeable.

Why isn't DSIP more widely used if it was discovered in the 1970s?

Results have been inconsistent across trials, its mechanism is still not fully understood, and no pharmaceutical company has successfully commercialized it. Newer sleep medications and clearer-mechanism drugs have dominated clinical development. DSIP remains primarily a research compound.

Can DSIP be taken orally?

Oral bioavailability is poor, peptides are generally broken down by gastric enzymes. Most research uses injection (subcutaneous, intramuscular, or IV) or intranasal administration.

References

Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA. 1977;74(3):1282-1286. PNAS
Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303-309. Journal of Neurochemistry
Schneider-Helmert D, Schoenenberger GA. Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology. 1983;9(4):197-206. PubMed
Larbig W, et al. DSIP in clinical treatment of chronic pain: a controlled study. Eur Neurol. 1984;23(6):372-385. PubMed
Dick P, et al. Successful DSIP-treatment in opiate withdrawal: comparative studies with methadone. Arzneimittelforschung. 1984;34(9A):1075-1078. PubMed
Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): an update. Peptides. 1986;7(6):1165-1187. PubMed

Disclaimer: This page is for educational and research purposes only. DSIP is not FDA-approved. Nothing here constitutes medical advice. Consult a licensed healthcare provider before using any peptide.